Kang-Yell Choi

Kang-Yell Choi, Ph.D. is a professor at Yonsei University and CEO of CK Regeon Inc.

The native form of this personal name is Choi Kang-Yell. This article uses Western name order when mentioning individuals.
In this Korean name, the family name is Choi.

Kang-Yell Choi completed his doctorate in Biochemistry at Purdue University in 1993. After completing his doctorate, Dr. Choi conducted research related to cell signaling at Harvard Medical School as a postdoctoral fellow. His research at Harvard investigated the function of Saccharomyces Ste5 involving pheromone response via MAP kinase pathway and was published as the1st paper introducing the concept of "Scaffold protein" in the community.

In 1995, Kang-Yell Choi returned to Korea as a professor at Yonsei University.[1] Since then, he has been working on mammalian cell signaling. Dr. Choi identified a novel mechanism of Ras stability regulation via the Wnt/beta-catenin signaling. The degradation of Ras, especially K-Ras, is controlled by GSK3-mediatedphosphorylation followed by ubiquitin-dependent proteasomal machinery via recruiting beta-TrCP E3 ligase. The stabilization of oncogenic K-Ras by APC loss and subsequent re-activation of the Wnt/beta-catenin pathway via positive loop through ERK activated cancer stem cells and induced liver metastasis of colorectal cancer. This indicates the importance of inhibition of both Wnt/beta-catenin and Ras-ERK pathways in the treatment of colorectal cancer.[2] He subsequently identified and characterized small molecules degrading both beta-catanin and Ras via targeting the Wnt/beta-catenin signaling, and those small molecules efficiently inhibit growth of colorectal and other cancers with activated Wnt/beta-catenin and EGFR-Ras pathways. He served as the Chief of the National Research Laboratory and Molecular Complex Control at Yonsei University for the past 5 years. He is currently positioned as the Director of the Translational Research Center for Protein Function Control (TRCP) supported by Korean National Research Foundation and Ministry of Science, ICT and Future Panning of Korea.

Department of Biotechnology, College of Life Science and Biotechnology, Yonsei University Translational Research Center for Protein Function Control, College of Life Science and Biotechnology, Yonsei University.

Education
  • 1978-1985 : BS, Department of Biotechnology, Yonsei University
  • 1988-1993 : Ph.D., Department of Biological Sciences, Biochemistry, Purdue University, USA
  • 1993-1995 : Post-doctor Harvard Medical School, Dept. of Biological Chemistry & Mol. Pharmacology, USA

Work summary

Professional experience:

  • 1995-1999 : Assistant Professor Dept of Biochem. & Mol. Biol. Col. of Medicine, Yonsei University
  • 2000-2001 : Associate Professor Dept of Biochem. & Mol. Biol., Dept. Biotech, Yonsei University
  • 2001-2003 : Associate Professor Dept of Biotechnology, College of Life Sci. Biotech., Yonsei University
  • 2004-Current : Professor Dept of Biotechnology, College of Life Sci. Biotech., Yonsei University

Professional service:

  • 1993-1995 : Post-doctor Harvard Medical School, Department of Biochemistry and Molecular Pharmacology
  • 2006-2007 : Chairman Graduate Studies of the Functional Genomics Program, Yonsei Univ.
  • 2000-2009 : Scientific Director Genepia Co.
  • 2006 : Member Selection committee for Korea top 10 development, Ministry of Industrial Affair
  • 2008-2011 : Review Board IRB for animal and human research, Yonsei University
  • 2008 : Visiting Scholar University of California San Diego
  • 2009 : Planning Review Board, Life Science (Korean Science Foundation)
  • 2004-2007 : Acting Director Research Institute of Global Leadership
  • 2004 : Member Board of Disease Control of Korean Government
  • 2004 : Member National Patent Attorney Test and Selection Committee of Korea
  • 2005-2009 : Chief National Research Laboratory (NRL)
  • 2004-Current : Advisory Board Cellular Dynamics Center, Research Center for Signaling Defect Bio-medical Research Center etc.
  • 2011-Current : Chief Do-Yak (2nd NRL)
  • 2008 : Visiting Professor Department of Molecular Pharmacology, UCSD
  • 2008-2010 : Chair, Department of Biotechnology, Yonsei University
  • 2009-Current : Director Translational Research Center for Protein Function Control, ERC
  • 2012 : Board Recommending member of Ho-Am (Sam Sung’s establisher) Prize
  • 2013 : Planning and Advisory Member, Enforcement pursue team of for evaluation of basic research, Ministry of Science, ICT and Future Planning, Korea
  • 2015 : Board, Evaluation Committee for Company Establishment, Yonsei University
  • 2015 : President, Korean Society for Cell Biology
  • 2016-Current : Chief, ERC center
  • 2016-Current : Underwood Distinguished Professor, Yonsei University
  • 2017 : Vice President, Korea Society for Molecular and Cellular Biology
  • 2017-Current : CEO, CK Regeon Inc. (Formerly CK Biotech Inc.)
  • 2019-Current : Vice President / Academic Chairman, Korean Society for Biochemistry and Molecular Biology

Publications

Publications (cited by pubmed)[3]

  • Yong-HeeCho, Eun JiRo, Jeong-SuYoon, Tomohiro Mizutani, Dong-Woo Kang, Jong-Chan Park,Tae Il Kim, Hans Clevers & K.Y. Choi.  5-FU promotes stemness ofcolorectal cancer via p53-mediated WNT/β-catenin pathway activation. Naturecommunications 11:5321 (2020)[4]
  • Jeong, WJ, Park, JC, Kim, WS, Ro, EJ, Jeon, SH, Lee, SK, Park YN, Min, DS, and Choi, KY. WDR76 is a RAS binding protein that functions as a tumor suppressor via RAS degradation. Nature Communications. 10(1):295. doi: 10.1038/s41467-018-08230-6. (2019)[5]
  • Lee, SK, WJ, Cho, YH, Cha, PH, Yoon JS, Ro EJ, Choi SH, Oh, JM, Heo,YS, Kim H, Min, DS, Han, G, Lee, W, Choi. KY. β-Catenin-RAS interaction serves as molecular switch for RAS degradation via GSK3β. EMBO Reports pii; e46060 (2018)[6]
  • Cha PH, Cho YH, Lee SK, Lee JH, Jeong W-J, Moon B-S, Yun JH, Yang JS, Choi SH, Yoon JY, Kim HY, Kim, MY, Kaduwal S, Lee W, Min DS, Kim Hg, Han GH, and Choi KY. Small molecule binding of the Axin-RGS domain promotes β-catenin and Ras degradation. Nature Chemical Biology. 12, 593-600 (2016)[7]
  • Kim, HY, Choi, S, Yoon JH, Lim HJ, Lee H, Choi J, Neo JN, Lee W, No, KT, and Choi, KY. Small molecule inhibitors of Dishevelled-CXXC5 interaction are new drug candidates for bone anabolic osteoporosis therapy. EMBO Molecular Medicine 8, 375-387 (2016)[8]
  • Kim, MY., Kim HY, Hong J., Kim D, Lee H, Cheong, E., Lee, Yangsin, Roth J., Kim, DG, Min DS., and Choi, KY. CXXC5 plays a role as a transcription activator for myelin genes on oligodendrocyte differentiation. Glia. 64(3), 350-362. (2016)[9]
  • Lee SH, Kim MY, Kim HY, Lee YM, Kim HS, Nam KA, Roh MR, Min DS, Chung KY, and Choi KY. The Dishevelled-binding protein CXXC5 negatively regulates cutaneous wound healing. Journal of Experimental Medicine. 212(7):1061-80. (2015)[10]
  • Kim HY, Yoon JY, Yoon JH, Cho KW, Lee, SH, Rhee, YM, Jung, HS, Lim HJ, Choi, JW, Heo JN, Lee WT, No KT, Min DS, and Choi KY. CXXC5 is a negative-feedback regulator of the Wnt/β-catenin pathway involved in osteoblast differentiation. Cell Death and Differentiation. 22(6):912-20. (2015)[11]
  • Moon, BS, Jeong, WJ, Park, J, Kim, TI, Min DS, and Choi, KY. Oncogenic K-Ras Accelerates Cancer Stem Cell Activation via Aberrant Wnt/beta-catenin Signaling. JNCI-Journal of the National Cancer Institute. 106(2):djt 373. (2014)[12]
  • Moon, BS, Cho, Y.H. Jeong, WJ, and Choi, KY. Response. JNCI-Journal of the National Cancer Institute. 106 (8): dju 197. (2014)[13]
  • Kim HY, Yang DH, Shin SW, Kim MY, Yoon JH, Kim S, Park HC, Kang DW, Min DS, Hur MW, and Choi KY. CXXC5 is a transcriptional activator of Flk-1 and mediates bone morphogenic protein-induced endothelial cell differentiation and vessel formation. FASEB Journal. 28(2), 615-26. (2014)[14]
  • Zahoor M, Cha PH, and Choi KY. Indirubin-3'-Oxime, an activator of Wnt/β-catenin signaling, enhances osteogenic commitment of ST2 cells and restore bone loss in high-fat diet-induced obese male mice. Bone. 65:60-68. (2014)[15]
  • Zahoor M, Cha PH, Min DS, and Choi KY. Indirubin-3’-oxime Reverses Bone Loss in Ovariectomized and Hindlimb-Unloaded Mice via Activation of the Wnt/β-Catenin Signaling. Journal of Bone and Mineral Research. 29:1196-1205. (2014)[16]
  • Choi OM, Cho YH, Choi S, Lee SH, Seo SH, Kim HY, Han GH, Park TS, Min DS, and Choi KY. The small molecule indirubin-3´-oxime activates Wnt/β-catenin signaling and inhibits adipocyte differentiation and obesity. International Journal of Obesity. 38:1044-52. (2014)[17]
  • Kim MY, Moon BS, and Choi KY. Isolation and maintenance of cortical neural progenitor cells in vitro. Methods in Molecular Biology. 1018:3-10. (2013) (IF=1.29) (“BookChapter”-Springer)[18]
  • Jeong WJ, Yoon JY, Park JC, Lee SH, Lee SH, Kaduwal S, Kim HG, Yoon JB, and Choi KY. Ras Stabilization via Aberrant Activation of Wnt/b-catenin Signaling Promotes Intestinal Tumorigenesis. Science Signaling. 5(219):ra30. (2012)[19]
  • Yoon JY, Koo KH, and Choi KY. MEK1/2 Inhibitors, AS703026 and AZD6244, may be potential therapies for K-ras Mutated Colorectal Cancer that Is resistant to EGFR Monoclonal Antibody Therapy. Cancer Research. 71(2):445-53. (2011)[20]
  • Moon BS, Kim HY, Kim MY, Yang DH, Lee JM, Cho KW, Jung HS, and Choi KY. Sur8/Shoc2 Involves Both Inhibition of Differentiation and Maintenance of Self-renewal of Neural Progenitor Cells via Modulation of ERK Signaling. Stem Cells. 29:320-31 (2011)[21]
  • Yang DH, Yoon JY, Lee SH, Bryja V, Andersson ER, Arenas E, Kwon YG, and Choi KY. Wnt5a Is Required for Endothelial Differentiation of Embryonic Stem Cells and Vascularization via Pathways Involving Both Wnt/β-Catenin and Protein Kinase Ca. Circulation Research. 104(3):372-9. (2009)[22]
  • Schumacher MA, Choi KY, Lu F, Zalkin H, and Brennan RG. Mechanism of corepressor-mediated specific DNA binding by the purine repressor. Cell. 83(1):147-55. (1995)[23]
  • Choi KY, Satterberg B, Lyons DM, and Elion EA. Ste5 thether multiple protein kinase in the MAP kinase cascade required for mating in Saccharomyces cerevisiae. Cell. 78(3):499-512. (1994)[24]
  • Schumacher MA, Choi KY, Zalkin H, and Brennan RG. Crystal structure of LacI member RurR, bound to DNA: Minor groove binding by α helices. Science. 266(5186):763-70. (1994)[25]

References
  1. "Archived copy". Archived from the original on 2016-03-15. Retrieved 2016-03-29.CS1 maint: archived copy as title (link)
  2. Jeong, Woo-Jeong; Yoon, Juyong; Park, Jong-Chan; Lee, Soung-Hoon; Lee, Seung-Hoon; Kaduwal, Saluja; Kim, Hoguen; Yoon, Jong-Bok; Choi, Kang-Yell (2012). "Ras Stabilization Through Aberrant Activation of WNT/β-Catenin Signaling Promotes Intestinal Tumorigenesis". Science Signaling. 5 (219): ra30. doi:10.1126/scisignal.2002242. PMID 22494971. S2CID 23999385.
  3. "PubMed".
  4. Cho, Yong-Hee; Ro, Eun Ji; Yoon, Jeong-Su; Mizutani, Tomohiro; Kang, Dong-Woo; Park, Jong-Chan; Il Kim, Tae; Clevers, Hans; Choi, Kang-Yell (2020-10-21). "5-FU promotes stemness of colorectal cancer via p53-mediated WNT/β-catenin pathway activation". Nature Communications. 11 (1): 5321. Bibcode:2020NatCo..11.5321C. doi:10.1038/s41467-020-19173-2. ISSN 2041-1723. PMC 7578039. PMID 33087710.
  5. Jeong, Woo-Jeong; Park, Jong-Chan; Kim, Woo-Shin; Ro, Eun Ji; Jeon, Soung Hoo; Lee, Sang-Kyu; Park, Young Nyun; Min, Do Sik; Choi, Kang-Yell (December 2019). "WDR76 is a RAS binding protein that functions as a tumor suppressor via RAS degradation". Nature Communications. 10 (1): 295. Bibcode:2019NatCo..10..295J. doi:10.1038/s41467-018-08230-6. ISSN 2041-1723. PMC 6336889. PMID 30655611.
  6. Lee, Sang‐Kyu; Jeong, Woo‐Jeong; Cho, Yong‐Hee; Cha, Pu‐Hyeon; Yoon, Jeong‐Su; Ro, Eun Ji; Choi, Sooho; Oh, Jeong‐Min; Heo, Yunseok; Kim, Hyuntae; Min, Do Sik (2018-11-09). "β‐Catenin‐ RAS interaction serves as a molecular switch for RAS degradation via GSK 3β". EMBO Reports. 19 (12). doi:10.15252/embr.201846060. ISSN 1469-221X. PMC 6280641. PMID 30413483.
  7. Cha, Pu-Hyeon; Cho, Yong-Hee; Lee, Sang-Kyu; Lee, JaeHeon; Jeong, Woo-Jeong; Moon, Byoung-San; Yun, Ji-Hye; Yang, Jee Sun; Choi, Sooho; Yoon, Juyong; Kim, Hyun-Yi (2016-06-13). "Small-molecule binding of the axin RGS domain promotes β-catenin and Ras degradation". Nature Chemical Biology. 12 (8): 593–600. doi:10.1038/nchembio.2103. ISSN 1552-4450. PMID 27294323.
  8. Kim, Hyun‐Yi; Choi, Sehee; Yoon, Ji‐Hye; Lim, Hwan Jung; Lee, Hyuk; Choi, Jiwon; Ro, Eun Ji; Heo, Jung‐Nyoung; Lee, Weontae; No, Kyoung Tai; Choi, Kang‐Yell (2016-03-03). "Small molecule inhibitors of the Dishevelled‐ CXXC 5 interaction are new drug candidates for bone anabolic osteoporosis therapy". EMBO Molecular Medicine. 8 (4): 375–387. doi:10.15252/emmm.201505714. ISSN 1757-4676. PMC 4818757. PMID 26941261.
  9. Kim, Mi-Yeon; Kim, Hyun-Yi; Hong, Jiso; Kim, Daesoo; Lee, Hyojung; Cheong, Eunji; Lee, Yangsin; Roth, Jürgen; Kim, Dong Goo; Min, Do Sik; Choi, Kang-Yell (2015-10-14). "CXXC5 plays a role as a transcription activator for myelin genes on oligodendrocyte differentiation". Glia. 64 (3): 350–362. doi:10.1002/glia.22932. ISSN 0894-1491. PMID 26462610. S2CID 2997358.
  10. Lee, Soung-Hoon; Kim, Mi-Yeon; Kim, Hyun-Yi; Lee, Young-Mi; Kim, Heesu; Nam, Kyoung Ae; Roh, Mi Ryung; Min, Do Sik; Chung, Kee Yang; Choi, Kang-Yell (2015-06-08). "The Dishevelled-binding protein CXXC5 negatively regulates cutaneous wound healing". Journal of Experimental Medicine. 212 (7): 1061–1080. doi:10.1084/jem.20141601. ISSN 1540-9538. PMC 4493411. PMID 26056233.
  11. Kim, H-Y; Yoon, J-Y; Yun, J-H; Cho, K-W; Lee, S-H; Rhee, Y-M; Jung, H-S; Lim, H J; Lee, H; Choi, J; Heo, J-N (2015-01-30). "CXXC5 is a negative-feedback regulator of the Wnt/β-catenin pathway involved in osteoblast differentiation". Cell Death & Differentiation. 22 (6): 912–920. doi:10.1038/cdd.2014.238. ISSN 1350-9047. PMC 4423189. PMID 25633194.
  12. Moon, Byoung-San; Jeong, Woo-Jeong; Choi, Kang-Yell (December 2014). "Abstract A50: Oncogenic K-Ras accelerates cancer stem cell activation via aberrant Wnt/β-catenin signaling". RAS Regulation. American Association for Cancer Research. 12 (12 Supplement): A50. doi:10.1158/1557-3125.rasonc14-a50.
  13. Moon, B.-S.; Cho, Y. H.; Jeong, W.-J.; Choi, K.-Y. (2014-08-18). "Response". JNCI Journal of the National Cancer Institute. 106 (8): dju197. doi:10.1093/jnci/dju197. ISSN 0027-8874. PMID 25136033.
  14. Kim, Hyun‐Yi; Yang, Dong‐Hwa; Shin, Song‐Weon; Kim, Mi‐Yeon; Yoon, Jae‐Hyun; Kim, Suhyun; Park, Hae‐Chul; Kang, Dong Woo; Min, DoSik; Hur, Man‐Wook; Choi, Kang‐Yell (2013-10-17). "CXXC5 is a transcriptional activator of Flk‐1 and mediates bone morphogenic protein‐induced endothelial cell differentiation and vessel formation". The FASEB Journal. 28 (2): 615–626. doi:10.1096/fj.13-236216. ISSN 0892-6638. PMID 24136587. S2CID 23959096.
  15. Zahoor, Muhammad; Cha, Pu-Hyeon; Choi, Kang-Yell (August 2014). "Indirubin-3′-oxime, an activator of Wnt/β-catenin signaling, enhances osteogenic commitment of ST2 cells and restores bone loss in high-fat diet-induced obese male mice". Bone. 65: 60–68. doi:10.1016/j.bone.2014.05.003. ISSN 8756-3282. PMID 24815917.
  16. Zahoor, Muhammad; Cha, Pu-Hyeon; Min, Do Sik; Choi, Kang-Yell (2014-04-22). "Indirubin-3′-Oxime Reverses Bone Loss in Ovariectomized and Hindlimb-Unloaded Mice Via Activation of the Wnt/β-Catenin Signaling". Journal of Bone and Mineral Research. 29 (5): 1196–1205. doi:10.1002/jbmr.2147. ISSN 0884-0431. PMID 24243753. S2CID 206006040.
  17. Choi, O M; Cho, Y-H; Choi, S; Lee, S-H; Seo, S H; Kim, H-Y; Han, G; Min, D S; Park, T; Choi, K Y (2013-11-15). "The small molecule indirubin-3′-oxime activates Wnt/β-catenin signaling and inhibits adipocyte differentiation and obesity". International Journal of Obesity. 38 (8): 1044–1052. doi:10.1038/ijo.2013.209. ISSN 0307-0565. PMC 4125748. PMID 24232498.
  18. Kim, Mi-Yeon; Moon, Byoung-San; Choi, Kang-Yell (2013), Isolation and Maintenance of Cortical Neural Progenitor Cells In Vitro, Methods in Molecular Biology, 1018, Totowa, NJ: Humana Press, pp. 3–10, doi:10.1007/978-1-62703-444-9_1, ISBN 978-1-62703-443-2, PMID 23681612, retrieved 2021-07-19
  19. Jeong, W.-J.; Yoon, J.; Park, J.-C.; Lee, S.-H.; Lee, S.-H.; Kaduwal, S.; Kim, H.; Yoon, J.-B.; Choi, K.-Y. (2012-04-10). "Ras Stabilization Through Aberrant Activation of Wnt/ -Catenin Signaling Promotes Intestinal Tumorigenesis". Science Signaling. 5 (219): ra30. doi:10.1126/scisignal.2002242. ISSN 1945-0877. PMID 22494971. S2CID 23999385.
  20. Yoon, Juyong; Koo, Kyoung-Hwa; Choi, Kang-Yell (2010-11-30). "MEK1/2 Inhibitors AS703026 and AZD6244 May Be Potential Therapies for KRAS Mutated Colorectal Cancer That Is Resistant to EGFR Monoclonal Antibody Therapy". Cancer Research. 71 (2): 445–453. doi:10.1158/0008-5472.can-10-3058. ISSN 0008-5472. PMID 21118963.
  21. Moon, Byoung-San; Kim, Hyun-Yi; Kim, Mi-Yeon; Yang, Dong-Hwa; Lee, Jong-Min; Cho, Kyoung-Won; Jung, Han-Sung; Choi, Kang-Yell (February 2011). "Sur8/Shoc2 Involves Both Inhibition of Differentiation and Maintenance of Self-Renewal of Neural Progenitor Cells via Modulation of Extracellular Signal-Regulated Kinase Signaling". Stem Cells. 29 (2): 320–331. doi:10.1002/stem.586. ISSN 1066-5099. PMID 21732489. S2CID 39465576.
  22. Yang, Dong-Hwa; Yoon, Ju-Young; Lee, Soung-Hoon; Bryja, Vitezslav; Andersson, Emma R.; Arenas, Ernest; Kwon, Young-Guen; Choi, Kang-Yell (2009-02-13). "Wnt5a Is Required for Endothelial Differentiation of Embryonic Stem Cells and Vascularization via Pathways Involving Both Wnt/β-Catenin and Protein Kinase Cα". Circulation Research. 104 (3): 372–379. doi:10.1161/circresaha.108.185405. ISSN 0009-7330. PMID 19096028. S2CID 44433895.
  23. Schumacher, Maria A.; Choi, Kang Yell; Lu, Fu; Zalkin, Howard; Brennan, Richard G. (October 1995). "Mechanism of corepressor-mediated specific DNA binding by the purine repressor". Cell. 83 (1): 147–155. doi:10.1016/0092-8674(95)90243-0. ISSN 0092-8674. PMID 7553867. S2CID 8776672.
  24. Chol, Kang-Yell; Satterberg, Brett; Lyons, David M.; Elion, Elaine A. (August 1994). "Ste5 tethers multiple protein kinases in the MAP kinase cascade required for mating in S. cerevisiae". Cell. 78 (3): 499–512. doi:10.1016/0092-8674(94)90427-8. ISSN 0092-8674. PMID 8062390. S2CID 20541545.
  25. Schumacher, M.; Choi, K.; Zalkin, H; Brennan, R. (1994-11-04). "Crystal structure of LacI member, PurR, bound to DNA: minor groove binding by alpha helices". Science. 266 (5186): 763–770. Bibcode:1994Sci...266..763S. doi:10.1126/science.7973627. ISSN 0036-8075. PMID 7973627.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.